Literature DB >> 28800311

Prognostic value of combined and individual expression of microRNA-1290 and its target gene nuclear factor I/X in human esophageal squamous cell carcinoma.

Rui Xie, Shang-Nong Wu, Cheng-Cheng Gao, Xiao-Zhong Yang, Hong-Gang Wang, Jia-Ling Zhang, Wei Yan, Tian-Heng Ma.   

Abstract

BACKGROUND: microRNA (miR)-1290 was previously indicated to promote esophageal squamous cell carcinoma (ESCC) progression via regulating its target gene nuclear factor I/X (NFIX).
OBJECTIVE: To investigate clinical significance of miR-1290 and NFIX in ESCC.
METHODS: Quantitative real-time PCR was performed to detect miR-1290 and NFIX mRNA expression in ESCC tissues. Associations of miR-1290 and/or NFIX mRNA expression with various clinicopathological features and prognosis in ESCC patients were statistically evaluated.
RESULTS: Compared to noncancerous esophageal mucosa, miR-1290 expression was upregulated, while NFIX mRNA expression was downregulated in ESCC tissues. There was a significantly negative correlation between miR-1290 and NFIX expression in ESCC tissues (r=-0.427, P= 0.01). Interestingly, miR-1290-high and/or NFIX-low expression were all significantly associated with positive lymph node metastasis and advanced tumor-node-metastasis stage of ESCC patients (all P< 0.05). Moreover, miR-1290 upregulation and NFIX downregulation both correlated short overall and disease-free survivals of ESCC patients. Importantly, the prognostic value of combined miR-1290 and NFIX expression was more significant than those considered alone.
CONCLUSIONS: Our data suggest that the dysregulation of miR-1290-NFIX axis may play crucial roles in esophageal carcinogenesis and progression. We also confirmed miR-1290 and its target gene NFIX as independent prognostic factors for ESCC patients.

Entities:  

Keywords:  Esophageal squamous cell carcinoma; clinicopathological characteristics; microRNA-1290; nuclear factor i/X; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28800311     DOI: 10.3233/CBM-170029

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  7 in total

1.  Prognostic Value of MicroRNAs in Esophageal Carcinoma: A Meta-Analysis.

Authors:  Song Gao; Zhi-Ying Zhao; Zhen-Yong Zhang; Yue Zhang; Rong Wu
Journal:  Clin Transl Gastroenterol       Date:  2018-11-13       Impact factor: 4.488

2.  LncRNA ZNF667-AS1 Promotes ABLIM1 Expression by Adsorbing micro RNA-1290 to Suppress Nasopharyngeal Carcinoma Cell Progression.

Authors:  Xi Chen; Yaping Huang; Dianyu Shi; Chuan Nie; Yiping Luo; Liangfen Guo; Yu Zou; Chun Xie
Journal:  Onco Targets Ther       Date:  2020-05-20       Impact factor: 4.147

3.  Mechanistic Signatures of Human Papillomavirus Insertions in Anal Squamous Cell Carcinomas.

Authors:  Adeline Morel; Cindy Neuzillet; Maxime Wack; Sonia Lameiras; Sophie Vacher; Marc Deloger; Nicolas Servant; David Veyer; Hélène Péré; Odette Mariani; Sylvain Baulande; Roman Rouzier; Maud Kamal; Elsy El Alam; Emmanuelle Jeannot; Alain Nicolas; Ivan Bièche; Wulfran Cacheux
Journal:  Cancers (Basel)       Date:  2019-11-22       Impact factor: 6.639

Review 4.  An Insight into miR-1290: An Oncogenic miRNA with Diagnostic Potential.

Authors:  Małgorzata Guz; Witold Jeleniewicz; Marek Cybulski
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

5.  Identification of a novel circ_0001946/miR-1290/SOX6 ceRNA network in esophageal squamous cell cancer.

Authors:  Jianjun Wang; Wenjian Yao; Jiwei Li; Quan Zhang; Li Wei
Journal:  Thorac Cancer       Date:  2022-04-12       Impact factor: 3.500

Review 6.  Regulatory Roles of Noncoding RNAs in the Progression of Gastrointestinal Cancers and Health Disparities.

Authors:  Aditi Kulkarni; Sharan Gayathrinathan; Soumya Nair; Anamika Basu; Taslim A Al-Hilal; Sourav Roy
Journal:  Cells       Date:  2022-08-07       Impact factor: 7.666

7.  A 10‑microRNA prognosis scoring system in esophageal squamous cell carcinoma constructed using bioinformatic methods.

Authors:  Qingchao Sun; Liang Zong; Haiping Zhang; Yanchao Deng; Changming Zhang; Liwei Zhang
Journal:  Mol Med Rep       Date:  2018-02-02       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.